DGX
$242.56-0.16%
as of close, Oct 27, 2026
☾ AH $242.56 -0.16%
Quest Diagnostics IncorporatedStock · HealthcareS&P 500 Equal Weight · 0.2% of RSPS&P 500 · 0.04% of SPYRussell 1000 · 0.03% of IWBUS Stock Market · 0.03% of VTIRussell 3000 · 0.03% of IWVMSCI World · 0.03% of URTHMSCI ACWI · 0.03% of ACWI
DGX — Quest Diagnostics Incorporated price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
VolumeDDDDDDDDDDDDDDDDDDDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDE
80.0100.0120.0140.0160.0180.0200.0220.0240.0010.0M$242.56—20162019202120242026
2026-10-27
Price$242.56
MA20$223.36
MA50$202.63
Vol4.5M
Key stats#
Price data
- Price
- $242.56
- YTD price return
- +39.78%
- YTD total return
- +42.13%
- Market cap
- 26.7B
- Enterprise value
- 32.5B
- Shares outstanding
- 110M
- 52W low
- $171.18
- 52W high
- $248.84
- From 52W high
- -2.52%
- From 52W low
- +41.70%
- 52W range
- 92%
- Beta
- 0.55
Volume
- Rel volume
- 0.81×
- 30D volume
- 1.1M
- 30D $ vol
- 268.4M
Insider trading
- Insider net 1W
- none
- Insider net 1M
- none
- Insider net 3M
- −$7.9M
- Insider net 1Y
- −$24.7M
Form 4 transactions by trade date, as filed; latest on file 2026-09-01.
Fundamentals
- Sales (ttm)
- 11.8B
- Sales/share
- $107.63
- EPS (ttm)
- $10.06
- FCF (ttm)
- 1.4B
- FCF/share
- $12.50
- Book value/share
- $69.37
- Net margin
- 9.53%
- ROE
- 14.79%
- ROA
- 6.56%
- Debt / equity
- 0.73×
- Current ratio
- 1.70
Growth (CAGR, ttm) · 10Y
- Sales
- +9.14%+8.39%+1.40%+4.67%
- Net income
- +16.52%+13.95%-12.36%+5.23%
- FCF
- -1.29%+32.13%-5.99%+5.86%
- Shares
- -1.10%-0.72%-2.15%-2.29%
Per-share growth (CAGR, ttm) · 10Y
- EPS
- +18.08%+14.54%-9.59%+7.88%
- Sales/share
- +10.35%+9.18%+3.63%+7.12%
- FCF/share
- -0.19%+33.09%-3.92%+8.34%
- Book value/share
- +6.33%+6.67%+5.89%+7.51%
- Dividend/share
- +7.31%+6.60%+6.91%+7.90%
- Price
- +34.59%+23.84%+11.00%+11.71%
- Total return
- +36.85%+26.21%+13.17%+13.93%
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- 24.1×
- P/OI (ttm)
- 15.5×
- Fwd P/E
- 20.2×
- P/S (ttm)
- 2.3×
- P/B (mrq)
- 3.5×
- P/FCF (ttm)
- 19.4×
- EV/EBITDA (fy)
- 14.1×
- EV/Sales (ttm)
- 2.7×
- FCF yield (ttm)
- 5.15%
- Dividend yield (fwd)
- 1.42%
- Dividend yield (ttm)
- 1.39%
- Dividend/share (fwd)
- $3.44
- Buyback yield (realized, 1y)
- 1.10%
- Shareholder yield (realized, 1y)
- 2.84%
- Buyback yield (cash, ttm)
- 2.07%
- Shareholder yield (cash, ttm)
- 3.45%
Vs own 10Y history
- P/E
- 98th
- P/OI
- 98th
- P/S
- 98th
- P/B
- 99th
- P/FCF
- 92nd
Bar = where today’s multiple sits in DGX’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).
Performance · price return · as of 2026-10-27#
1D
-0.16%
5D
+2.29%
1M
+2.64%
3M
+4.62%
YTD
+39.78%
1Y
+34.56%
5Y
+68.51%
Recent filings#
- Oct 22Earnings · Earnings release — EPS $3.00 vs $2.85 est. (+5.3%); revenue $3.10B (+10% y/y) 1.8%
- Jul 23Earnings · Earnings release — EPS $3.12 vs $2.81 est. (+11.0%); revenue $3.04B (+10% y/y) 8.6%
Financial statements
Open full DGX financials →Loading financial statements…
Related Healthcare#
| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +8.32% | +0.22% |
| JNJ | Johnson & Johnson | -0.92% | +0.91% |
| ABBV | AbbVie Inc. | +8.34% | -0.12% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | +8.98% | -0.08% |
| MRK | Merck & Co. Inc. | -4.68% | +0.86% |
| NVS | Novartis AG | +7.84% | +1.98% |
| TMO | Thermo Fisher Scientific Inc. | +2.67% | +1.19% |
| AMGN | Amgen Inc. | +8.04% | +0.75% |
